New Mesothelioma Drug Discovered in Sea Squirt Toxin
A unique drug derived from the Caribbean sea squirt shows impressive effectiveness in stopping the growth of mesothelioma tumor cells.
Researchers at the Medical University of Vienna in Austria discovered that trabectedin, a toxin the coral-like animal uses against predators, might soon be applied in the treatment of mesothelioma.
“It has looked very promising to this point,” Walter Berger, group leader at the Institute of Cancer Research, University of Vienna, told Asbestos.com. “It’s a fascinating new substance — from its origins to its mode of action.”
A European pharmaceutical company has been harvesting th...
Source: Asbestos and Mesothelioma News - August 30, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: mesothelioma treatment sea squirt cancer treatment sea squirt trabectedin toxin sea toxin for cancer trabectedin for mesothelioma Source Type: news
Alisertib Shows Promise in Soft-Tissue Sarcoma
Alisertib yielded promising progression-free survival in advanced/metastatic soft-tissue sarcoma patients, though it did not meet its primary response rate endpoint. (Source: CancerNetwork)
Source: CancerNetwork - August 16, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news
Arkansas Hospice Adds Physician Robin Devan (Movers & Shakers)
Dr. Robin Devan of Little Rock has joined Arkansas Hospice as a physician for the central Arkansas area.
Devan has served as an assistant professor of palliative care at the Winthrop P. Rockefeller Cancer Institute and the University of Arkansas for Medical Sciences Hospital, as well as director of the UAMS Adult Sickle Cell Clinical Program.
Eric Burgener and Turner Sibley, physical therapists at Conway Regional Therapy Center-Scherman Heights, have been awarded board certification in orthopedics through the American Board of Physical Therapy Specialties.
Burgener is certified in workers’ comp rehabilitation, while...
Source: Arkansas Business - Health Care - August 8, 2016 Category: American Health Source Type: news
Scientists Trace Origin Cell of Bone and Soft Tissue Tumors, Test Drug Target
Contact: Samiha Khanna Phone: 919-419-5069 Email: samiha.khanna@duke.edu https://www.dukehealth.org
EMBARGOED FOR RELEASE until 12 p.m. (ET) on Thursday, July 14, 2016
DURHAM, N.C. -- Scientists at Duke Health are part of a team that has discovered a type of cell surrounding blood vessels can also serve as a starting point for sarcoma, a form of cancer that occurs in bones and connective tissues.
The findings, made through studies of mice, offer insights that could aid in the development of potential new treatments for the rare but devastating cancer, which has 15,000 new diagnoses annually in the U.S.
In an article to be ...
Source: DukeHealth.org: Duke Health Features - July 14, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news
What Are The Most Common Pediatric Cancers?
Discussion
Cancer occurs in all ages including children. Fortunately cancer is much less common in the pediatric age group accounting for <1% of all cancers yearly in the US. Approximately 10,000 US children under age 15 will be diagnosed with cancer in 2016. More than 80% of those children will survive more than 5 years because of advances in direct cancer treatment and treatment of its complications. Survival rates depend on a number of factors including the type of cancer and location. Despite these good numbers, about 1250 children in the US die yearly from pediatric cancer. After accidents, childhood cancer, suicid...
Source: PediatricEducation.org - July 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Unprecedented, But Puzzling, Results in Advanced SarcomaUnprecedented, But Puzzling, Results in Advanced Sarcoma
In soft tissue sarcoma, the investigational antibody olaratumab improved overall survival by a large margin and progression-free survival by a considerably smaller margin, which is unusual. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 14, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Chemo for Adult Sarcomas: Murky Data and Experts' InsightsChemo for Adult Sarcomas: Murky Data and Experts' Insights
The paucity of data on the relative benefits of chemotherapy in adult soft-tissue sarcomas muddies the clinical decision-making waters, say sarcoma experts, who offer some advice, anyway. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 27, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
[Perspective] The cancer predisposition revolution
Studies of rare cancer predisposition syndromes often lead to the identification of genes critical to carcinogenesis. In 1969, Li and Fraumeni described a constellation of various cancers in the family members of four unrelated children who were diagnosed with soft tissue sarcomas (1). They posited that the cancers best fit an autosomal dominant pattern of inheritance, attributable to a genetic defect. At that time, cancer was not generally thought of as a genetic disease. Their hypothesis set the stage for establishing germline mutations in the tumor suppressor gene TP53 as the underlying genetic event in Li-Fraumeni synd...
Source: ScienceNOW - May 26, 2016 Category: Science Authors: David Malkin Tags: Cancer Source Type: news
MSK surgeons present strategies for increasing survival in soft tissue sarcoma patients
(American Association for Thoracic Surgery) In a presentation at the 96th AATS Annual meeting, Neel P. Chudgar, M.D., from the Department of Surgery at Memorial Sloan Kettering Cancer Center presents survival data and prognostic factors based on a large, single-institution database of STS patients who have undergone pulmonary metastasectomy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2016 Category: Cancer & Oncology Source Type: news
FDA Grants Priority Review For Lilly's Olaratumab, An Investigational Medicine For Advanced Soft Tissue Sarcoma
INDIANAPOLIS, May 4, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the biologics license application (BLA) for olaratumab, a PDGFRα... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 4, 2016 Category: Drugs & Pharmacology Source Type: news
Radiation may help after surgery for 'soft-tissue' cancers
HealthDay News Older patients with a type of cancer called soft-tissue sarcomas may benefit more from radiation therapy after surgery than younger patients do.. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 14, 2016 Category: Consumer Health News Source Type: news
Radiation May Help After Surgery for 'Soft-Tissue' Cancers
Biggest benefit was seen in people over 65, research suggests
Source: HealthDay
Related MedlinePlus Pages: Radiation Therapy, Soft Tissue Sarcoma, Surgery (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 14, 2016 Category: Consumer Health News Source Type: news
Radiation May Help After Surgery for 'Soft-Tissue' Cancers
THURSDAY, April 14, 2016 -- Older patients with a type of cancer called soft-tissue sarcomas may benefit more from radiation therapy after surgery than younger patients do, a new study suggests.
The results might change the way older patients are... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 14, 2016 Category: Journals (General) Source Type: news
Radiation improves survival in older patients with soft tissue sarcomas
Radiation therapy following surgery benefits older patients more than their younger counterparts, researchers report, a surprising finding that could change the way some patients are treated for soft tissue sarcomas (STS). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 11, 2016 Category: Science Source Type: news
